Hospitalisation rates in RAASi-naïve HFrEF patients
The aim of the Houchen et al. study was to compare real-world outcomes of Entresto® (sacubitril/valsartan) vs. angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy, in RAASi-naïve patients with HF and reduced...